FDA expands ANKTIVA BCG label to cover papillary NMIBC.
ImmunityBio announced an FDA expansion of the ANKTIVA plus BCG indication to include patients with BCG-unresponsive cystitis or papillary-only tumors. Market relevance: Expands commercial potential to an additional 85% of the target patient population.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed